News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Corey Pelletier

Articles by Corey Pelletier

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

ByElyse Swallow,Jessica Maitland,Kirthana Sarathy,Ellen Sears,Yasir Nagarwala,Janelle DePalantino,Eric Kruep,Corey Pelletier,Sebastian Kloss,Tomer Wasserman

April 18th 2025

37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model

37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model

ByGregory Vidal, MD, PhD,Frank Cinfio,Jack Badaracco,Corey Pelletier,Matthew Gitlin

June 22nd 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC

Precision Medicine and the “Slow Death” of Transplant in Lymphoma

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer